![]() |
市场调查报告书
商品编码
1514760
欧洲临床生物标记市场 - 分析与预测(2023-2033)Europe Clinical Biomarkers Market - Analysis and Forecast, 2023-2033 |
2023年欧洲临床生物标记市场规模达71.9亿美元。
预计2023年至2033年该市场将以7.52%的复合年增长率成长,2033年达到148.4亿美元。临床生物标记是可测量的生物因素,有助于早期诊断和了解疾病的进展。这些分子生物标记为疾病研究和治疗药物开发提供了新途径。
主要市场统计数据 | |
---|---|
预测期 | 2023-2033 |
2023年评估 | 71.9亿美元 |
2033 年预测 | 148.4亿美元 |
复合年增长率 | 7.52% |
在生物技术和分子生物学发展的推动下,欧洲临床生物标记市场正在显着扩张。临床生物标记是可测量的生物因素。它对于了解疾病的病程、帮助早期诊断和发现新的治疗标靶至关重要。预后、预测和诊断生物标记只是该领域众多基于生物标记的测试和相关服务的一小部分。推动该产业发展的三个关键驱动因素是:研发投资的增加、个人化治疗需求的增加以及慢性病盛行率的上升。此外,欧洲法规环境正在发生变化,以促进新型生物标记技术的创建和应用。为了满足不断增长的需求,顶级製造商和服务供应商正致力于扩大其产品阵容并提高技术力。
本报告考察了欧洲临床生物标记市场,概述了市场、国家趋势以及进入市场的公司概况。
Introduction to Europe Clinical Biomarkers Market
The Europe clinical biomarkers market was valued at $7.19 billion in 2023 and is expected to reach $14.84 billion by 2033, growing at a CAGR of 7.52% between 2023 and 2033. Clinical biomarkers are biological factors that can be measured to help in early diagnosis and understanding of the course of a disease. These molecular biomarkers provide new avenues for the study of diseases and the development of therapeutics. The producers of numerous biomarker-based tests, such as prognostic, predictive, and diagnostic biomarkers, as well as associated services, are highlighted in this research.
KEY MARKET STATISTICS | |
---|---|
Forecast Period | 2023 - 2033 |
2023 Evaluation | $7.19 Billion |
2033 Forecast | $14.84 Billion |
CAGR | 7.52% |
Market Introduction
The market for clinical biomarkers in Europe is expanding significantly, propelled by developments in biotechnology and molecular biology. Clinical biomarkers are biological factors that may be measured. They are essential for comprehending the course of disease, helping with early diagnosis, and discovering novel targets for treatment. Prognostic, predictive, and diagnostic biomarkers are only a few of the many biomarker-based tests available in this sector, along with associated services. Three major drivers are driving the industry forward: increased investments in research and development, growing desire for personalized treatment, and rising prevalence of chronic diseases. Furthermore, Europe's regulatory environment is changing to facilitate the creation and application of novel biomarker technologies. To meet the increasing demand, top manufacturers and service providers are concentrating on broadening their product offerings and improving their technological prowess. This report delves into the current market dynamics, key players, and future trends shaping the European clinical biomarkers market.
Market Segmentation
Segmentation 1: by Country
How can this report add value to an organization?
Growth/Marketing Strategy: Product launches and upgradations accounted for the maximum number of key developments, at nearly 59% of the total developments in the clinical biomarkers market between January 2019 and December 2023. Numerous synergistic activities, fundings, and acquisitions of the market have also been tracked during the same time period.
Competitive Strategy: The Europe clinical biomarkers market is a highly fragmented market, with many smaller and private companies constantly entering the market. Key players in the clinical biomarkers market analyzed and profiled in the study involve established players that offer various kinds of products and services.
Key Market Players and Competition Synopsis
The companies that are profiled have been selected based on inputs gathered from primary experts and analyzing company coverage, product portfolio, and market penetration.
Some prominent names established in this market are